Market Overview

Reveal Biosciences and Science Exchange Apply Artificial Intelligence to Pathology

Share:

Science Exchange, the leading marketplace for outsourced R&D™,
announces a collaboration with Reveal
Biosciences
to offer on-demand access to AI-based pathology services
worldwide.

Reveal Biosciences is a San Diego-based company that's leading the next
generation of quantitative histopathology, combining the latest
artificial intelligence (AI) techniques with high-quality histology,
immunohistochemistry (IHC) and in situ hybridization (ISH) to
generate enhanced data from tissue samples.

Reveal's AI-based tissue analysis utilizes trained pathology models to
recognize disease patterns in whole slide digital images. This service
can be applied to tumor profiling, quantitative immunohistochemistry,
NASH, toxicology and quantitative multiplexing. On top of that, Reveal
is generating disease-specific AI-based models as pathology decision
support tools to accelerate clinical trials for the benefit of patients.

"We are delighted to join forces with Science Exchange," said Claire
Weston, Ph.D., Founder and CEO of Reveal Biosciences. "I am confident
that our unique application of artificial intelligence to pathology will
benefit Science Exchange's life sciences community."

"The use of AI-based tools in pathology is expected to increase
significantly over time in both drug discovery and patient diagnostics
as it is more cost-effective, accurate, reproducible and scalable,"
stated Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange.
"Reveal Biosciences is the leader in employing an AI-based approach in
the pathology space, and we are thrilled to team up with them."

About Science Exchange

Science Exchange is the world's leading marketplace for outsourced
R&D™
, providing large R&D organizations with the fastest path
from discovery through development and commercialization. Science
Exchange includes an efficient source-to-secure platform for ordering
6,000+ services from a network of more than 2,500 qualified outsourced
research providers, all with pre-established contracts in place that
protect client intellectual property and confidentiality. The platform
increases access to innovation and improves productivity, freeing
scientists from administrative tasks and delays associated with
sourcing, establishing and managing service provider contracts.
Additionally, the Science Exchange enterprise program enables large R&D
organizations to consolidate research outsourcing spend into a single
strategic relationship, driving efficiency, improving transparency and
oversight, and delivering cost savings. Since being founded in 2011,
Science Exchange has raised more than $58 million from Norwest Venture
Partners, Maverick Capital Ventures, Union Square Ventures,
Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and
others. For more information, visit www.ScienceExchange.com.
Follow the company on Twitter @ScienceExchange,
Facebook
and LinkedIn.

About Reveal Biosciences

Reveal Biosciences is a San Diego-based computational pathology company
leveraging artificial intelligence (AI) to enable pathologists to make
diagnostic decisions faster, more accurately, and for less money. The
company also supports drug development by combining traditional
histopathology with AI to transform tissue biology into actionable data.
Reveal's portfolio includes in situ hybridization (ISH),
immunohistochemistry (IHC), immunofluorescence (IF), histopathology, and
whole slide imaging. Follow the company on Twitter @RevealBio, Instagram
@RevealBio, Facebook
and LinkedIn.

View Comments and Join the Discussion!